ATH-1020 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the safety and behavior of a new treatment, ATH-1020, in the body. It focuses on healthy young and older adults, testing the treatment in both single and multiple doses. The trial includes two groups: one receiving ATH-1020 and another receiving a placebo (a pill with no active ingredients). Individuals who are generally healthy, with no serious allergies or recent surgeries, might be suitable for this study. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial requires that participants do not use any chronic medications. If you use short-acting benzodiazepines or other treatments for insomnia and anxiety, you must stop using them during the screening period and throughout the study.
Is there any evidence suggesting that ATH-1020 is likely to be safe for humans?
Research shows that ATH-1020 is undergoing testing to determine its safety for humans. This marks the first use of ATH-1020 in people. The goal is to observe the body's reaction to the drug and identify any side effects.
Currently, there is no clear information on how well people tolerate ATH-1020 or what specific side effects might occur. As a first-in-human trial, the drug is in the early testing stages, meaning information about its safety in people is limited.
Despite the lack of previous human data, this phase of research focuses on ensuring the treatment's safety for further testing. Participants in these studies receive close monitoring for any negative effects, and researchers adjust dosages to establish a safe range.12345Why do researchers think this study treatment might be promising?
ATH-1020 is unique because it offers a new approach to treatment in its potential condition, targeting pathways that current options might not address. Unlike traditional medications that may require frequent administration or injections, ATH-1020 is administered orally, which could improve patient comfort and compliance. Researchers are excited about its innovative mechanism of action, which could offer benefits where existing treatments fall short, providing hope for more effective management of the condition.
What evidence suggests that ATH-1020 could be effective?
Research suggests that ATH-1020, which participants in this trial may receive, could help treat symptoms related to Parkinson's disease. Studies have shown it positively affects a system that supports nerve cell health. Early research indicates that ATH-1020 might reduce depression-like symptoms and improve sensory information processing in conditions like schizophrenia. These initial findings are promising for its potential use in diseases affecting the brain and nerves. However, more research with human participants is needed to confirm these effects.12678
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose (SAD)
Participants receive a single dose of ATH-1020 or placebo to evaluate safety, tolerability, and pharmacokinetics
Multiple Ascending Dose (MAD)
Participants receive multiple doses of ATH-1020 or placebo to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ATH-1020
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Athira Pharma
Lead Sponsor
Biotrial Inc.
Collaborator
Alturas Analytics, Inc.
Collaborator